Case Reports

Neuroendocrine carcinoma of the larynx with metastasis to the eyelid


 

Neuroendocrine tumors are a rare type of neoplasms that comprise only 0.5% of all malignancies.1 They usually arise from the gastrointestinal tract and the lung.1,2 Neuroendocrine carcinoma of the head and neck is a relatively rare malignancy described in the literature. The larynx is the most commonly affected region of the head and neck.3,4 Nevertheless, small-cell carcinoma comprises only 0.5% of all laryngeal cancers.5 Neuroendocrine carcinoma of the larynx carries variable prognosis depending on the histological subtype.6 Typical carcinoid rarely metastasizes, but atypical carcinoid and small-cell carcinoma have high rates of metastasis, usually in the lung and liver.2 Cutaneous metastasis from neuroendocrine carcinoma is an extremely rare entity, with only few cases reported in the English literature.7,8 We report the case of an elderly man with recurrent laryngeal neuroendocrine carcinoma with metastasis to the eyelid.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Harnessing new data on immunotherapies
MDedge Hematology and Oncology
Similar outcomes for salvage vs. planned surgery after chemoradiotherapy in esophageal cancer
MDedge Hematology and Oncology
Persistent HPV16 DNA in oral rinse signaled oropharyngeal cancer’s return
MDedge Hematology and Oncology
ESTIMABL trial: Current rhTSH cost outweighs benefits
MDedge Hematology and Oncology
JCO publishes special issue on head and neck cancers
MDedge Hematology and Oncology
Radiation field optimization may preserve salivary gland function
MDedge Hematology and Oncology
ECC: Pembrolizumab hits mark in heavily pretreated nasopharngeal cancer
MDedge Hematology and Oncology
No link between head and neck cancers and marijuana use
MDedge Hematology and Oncology
Look for tweaks to RAI, genomic analyses, and targeted treatment for thyroid cancer at ATA
MDedge Hematology and Oncology
Hospitalizations of more than 5 days predict for worse outcomes after radiotherapy for head and neck cancer
MDedge Hematology and Oncology